Baird analyst Joel Beatty raised the firm’s price target on Axsome Therapeutics (AXSM) to $132 from $116 and keeps an Outperform rating on the shares. The firm said the approval of AXS-07 shifts the focus to a trio of Phase 3 readouts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics hosts SYMBRAVO FDA approval investor event
- Axsome Therapeutics price target raised to $190 from $180 at H.C. Wainwright
- Axsome Therapeutics announces FDA approval of Symbravo
- Axsome Therapeutics price target raised to $155 from $125 at TD Cowen
- Axsome Therapeutics participates in a conference call with William Blair